Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.

Murali B, Ren Q, Luo X, Faget DV, Wang C, Johnson RM, Gruosso T, Flanagan KC, Fu Y, Leahy K, Alspach E, Su X, Ross MH, Burnette B, Weilbaecher KN, Park M, Mbalaviele G, Monahan JB, Stewart SA.

Cancer Res. 2018 Oct 1;78(19):5618-5630. doi: 10.1158/0008-5472.CAN-18-0234. Epub 2018 Aug 9.

PMID:
30093561
2.

The β3-integrin endothelial adhesome regulates microtubule-dependent cell migration.

Atkinson SJ, Gontarczyk AM, Alghamdi AA, Ellison TS, Johnson RT, Fowler WJ, Kirkup BM, Silva BC, Harry BE, Schneider JG, Weilbaecher KN, Mogensen MM, Bass MD, Parsons M, Edwards DR, Robinson SD.

EMBO Rep. 2018 Jul;19(7). pii: e44578. doi: 10.15252/embr.201744578. Epub 2018 May 24.

3.

Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.

Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG.

Nat Commun. 2018 Mar 28;9(1):1250. doi: 10.1038/s41467-018-03600-6.

4.

Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes.

Miller J, Wang ST, Orukari I, Prior J, Sudlow G, Su X, Liang K, Tang R, Hillman EMC, Weilbaecher KN, Culver JP, Berezin MY, Achilefu S.

J Biophotonics. 2018 Apr;11(4):e201700232. doi: 10.1002/jbio.201700232. Epub 2018 Jan 3.

PMID:
29206348
5.

HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice.

Esser AK, Rauch DA, Xiang J, Harding JC, Kohart NA, Ross MH, Su X, Wu K, Huey D, Xu Y, Vij K, Green PL, Rosol TJ, Niewiesk S, Ratner L, Weilbaecher KN.

Oncotarget. 2017 Aug 27;8(41):69250-69263. doi: 10.18632/oncotarget.20565. eCollection 2017 Sep 19.

6.

Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack J, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN.

Cancer Res. 2017 Nov 15;77(22):6299-6312. doi: 10.1158/0008-5472.CAN-17-1225. Epub 2017 Aug 30.

7.

Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.

Fontana F, Ge X, Su X, Hathi D, Xiang J, Cenci S, Civitelli R, Shoghi KI, Akers WJ, D'avignon A, Weilbaecher KN, Shokeen M.

Clin Cancer Res. 2017 Jan 15;23(2):416-429. doi: 10.1158/1078-0432.CCR-15-2134. Epub 2016 Aug 2.

8.

Antagonizing Integrin β3 Increases Immunosuppression in Cancer.

Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN.

Cancer Res. 2016 Jun 15;76(12):3484-95. doi: 10.1158/0008-5472.CAN-15-2663. Epub 2016 May 23.

9.

Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development.

Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, Gang M, Su X, Zamani A, Shi Y, Lavine KJ, Ornitz DM, Weilbaecher KN, Long F, Novack DV, Faccio R, Longmore GD, Stewart SA.

Cell Rep. 2016 Jan 5;14(1):82-92. doi: 10.1016/j.celrep.2015.12.016. Epub 2015 Dec 24.

10.

Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.

Esser AK, Schmieder AH, Ross MH, Xiang J, Su X, Cui G, Zhang H, Yang X, Allen JS, Williams T, Wickline SA, Pan D, Lanza GM, Weilbaecher KN.

Nanomedicine. 2016 Jan;12(1):201-11. doi: 10.1016/j.nano.2015.10.003. Epub 2015 Oct 27.

11.

Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.

Pan D, Pham CT, Weilbaecher KN, Tomasson MH, Wickline SA, Lanza GM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jan-Feb;8(1):85-106. doi: 10.1002/wnan.1355. Epub 2015 Aug 21. Review.

12.

CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.

Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN.

Mol Cancer Ther. 2015 Nov;14(11):2473-85. doi: 10.1158/1535-7163.MCT-15-0252. Epub 2015 Aug 12.

13.

Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types.

Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O'Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH.

PLoS One. 2015 May 28;10(5):e0127828. doi: 10.1371/journal.pone.0127828. eCollection 2015.

14.

Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.

Soodgupta D, Pan D, Cui G, Senpan A, Yang X, Lu L, Weilbaecher KN, Prochownik EV, Lanza GM, Tomasson MH.

Mol Cancer Ther. 2015 Jun;14(6):1286-1294. doi: 10.1158/1535-7163.MCT-14-0774-T. Epub 2015 Mar 30.

15.

Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts.

Amend SR, Uluckan O, Hurchla M, Leib D, Novack DV, Silva M, Frazier W, Weilbaecher KN.

J Bone Miner Res. 2015 Jan;30(1):106-15. doi: 10.1002/jbmr.2308.

16.

A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer.

Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, Johnson F, Eby CS, Weilbaecher KN.

Clin Breast Cancer. 2013 Dec;13(6):409-15. doi: 10.1016/j.clbc.2013.08.006.

17.

Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH, Shokeen M.

PLoS One. 2013;8(2):e55841. doi: 10.1371/journal.pone.0055841. Epub 2013 Feb 8. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/8532e291-73d3-461c-810d-0533ccb1eba0.

18.

Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.

Zheng D, Decker KF, Zhou T, Chen J, Qi Z, Jacobs K, Weilbaecher KN, Corey E, Long F, Jia L.

Mol Cancer Res. 2013 May;11(5):482-93. doi: 10.1158/1541-7786.MCR-12-0520. Epub 2013 Feb 5.

19.

Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.

Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV.

Cancer Discov. 2013 Feb;3(2):212-23. doi: 10.1158/2159-8290.CD-12-0271. Epub 2012 Dec 26.

20.

Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis.

Hurchla MA, Weilbaecher KN.

Oncoimmunology. 2012 Nov 1;1(8):1411-1413.

21.

Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.

Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ.

ACS Chem Biol. 2013 Mar 15;8(3):578-87. doi: 10.1021/cb300568r. Epub 2012 Dec 11.

22.

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN.

J Clin Invest. 2012 Oct;122(10):3579-92. doi: 10.1172/JCI38576. Epub 2012 Sep 17.

23.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

24.

Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter.

Chinault SL, Prior JL, Kaltenbronn KM, Penly A, Weilbaecher KN, Piwnica-Worms D, Blumer KJ.

Clin Cancer Res. 2012 Aug 1;18(15):4136-44. doi: 10.1158/1078-0432.CCR-12-0642. Epub 2012 Jun 12.

25.

Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment.

Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN.

Cancer Res. 2012 Feb 15;72(4):897-907. doi: 10.1158/0008-5472.CAN-11-2681. Epub 2011 Dec 20.

26.

Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.

Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ.

Mol Imaging Biol. 2012 Aug;14(4):500-8. doi: 10.1007/s11307-011-0512-4.

27.

Cancer to bone: a fatal attraction.

Weilbaecher KN, Guise TA, McCauley LK.

Nat Rev Cancer. 2011 Jun;11(6):411-25. doi: 10.1038/nrc3055. Epub 2011 May 19. Review.

28.

The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.

Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN.

PLoS One. 2010 Dec 30;5(12):e15755. doi: 10.1371/journal.pone.0015755.

29.

Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Schneider JG, Amend SR, Weilbaecher KN.

Bone. 2011 Jan;48(1):54-65. doi: 10.1016/j.bone.2010.09.016. Epub 2010 Sep 17. Review.

30.

The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?

Hirbe AC, Morgan EA, Weilbaecher KN.

Curr Pharm Des. 2010;16(11):1284-90. Review.

PMID:
20166978
31.

Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.

Morgan EA, Schneider JG, Baroni TE, Uluçkan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN.

FASEB J. 2010 Apr;24(4):1117-27. doi: 10.1096/fj.09-138420. Epub 2009 Nov 20.

32.

Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.

Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ.

J Nucl Med. 2009 Nov;50(11):1873-80. doi: 10.2967/jnumed.109.067140.

33.

CD47 regulates bone mass and tumor metastasis to bone.

Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN.

Cancer Res. 2009 Apr 1;69(7):3196-204. doi: 10.1158/0008-5472.CAN-08-3358. Epub 2009 Mar 10.

34.

Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN.

J Biol Chem. 2009 Feb 13;284(7):4658-66. doi: 10.1074/jbc.M804812200. Epub 2008 Dec 5.

35.

Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.

Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN.

Clin Cancer Res. 2008 Oct 15;14(20):6387-95. doi: 10.1158/1078-0432.CCR-08-1572. Review.

36.

Multiple facets of junD gene expression are atypical among AP-1 family members.

Hernandez JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K.

Oncogene. 2008 Aug 14;27(35):4757-67. doi: 10.1038/onc.2008.120. Epub 2008 Apr 21. Review.

37.

RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation.

Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, O'Neal J, Zou W, Weilbaecher KN, Faccio R, Novack DV.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3897-902. doi: 10.1073/pnas.0708576105. Epub 2008 Mar 5.

38.

Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.

Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL.

Clin Cancer Res. 2007 Sep 1;13(17):5001-9.

39.

Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.

Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN.

Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14062-7. Epub 2007 Aug 22.

40.

Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide.

Sprague JE, Kitaura H, Zou W, Ye Y, Achilefu S, Weilbaecher KN, Teitelbaum SL, Anderson CJ.

J Nucl Med. 2007 Feb;48(2):311-8.

41.

Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.

Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6209s-6212s.

42.

Platelet and osteoclast beta3 integrins are critical for bone metastasis.

Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10. Epub 2003 Nov 11.

43.

Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.

Sheffield MV, Yee H, Dorvault CC, Weilbaecher KN, Eltoum IA, Siegal GP, Fisher DE, Chhieng DC.

Am J Clin Pathol. 2002 Dec;118(6):930-6.

PMID:
12472287
44.

The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma.

Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, Weilbaecher KN, Schlegel W, Valent P, Wrba F, Pehamberger H, Fisher D, Jansen B.

Cancer Res. 2002 Apr 1;62(7):2098-103.

45.

Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.

Granter SR, Weilbaecher KN, Quigley C, Fisher DE.

Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):47-51.

PMID:
11893035
46.

Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice.

Weilbaecher KN, Motyckova G, Huber WE, Takemoto CM, Hemesath TJ, Xu Y, Hershey CL, Dowland NR, Wells AG, Fisher DE.

Mol Cell. 2001 Oct;8(4):749-58.

47.

Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.

Dorvault CC, Weilbaecher KN, Yee H, Fisher DE, Chiriboga LA, Xu Y, Chhieng DC.

Cancer. 2001 Oct 25;93(5):337-43.

PMID:
11668469
48.

Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.

Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE.

Am J Dermatopathol. 2001 Jun;23(3):185-9.

PMID:
11391097
49.

Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family.

Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, Fisher DE.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5798-803. Epub 2001 May 1.

50.

Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation.

Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE.

Mod Pathol. 2001 Jan;14(1):6-9.

Supplemental Content

Loading ...
Support Center